• Anterior chamber cell [ Time Frame: Days 1, 3, 7, 14, and 28 after surgery ] [ Designated as safety issue: No ]
  
• Anterior chamber flare [ Time Frame: Days 1, 3, 7, 14, and 28 after surgery ] [ Designated as safety issue: No ]
  
• Intraocular pressure [ Time Frame: Days 1, 3, 7, 14, and 28 after surgery ] [ Designated as safety issue: Yes ]
  
• Lack of anti-inflammatory response [ Time Frame: Days 1, 3, 7, 14, and 28 after surgery ] [ Designated as safety issue: Yes ]
  
• Presence of infection [ Time Frame: Days 1, 3, 7, 14, and 28 after surgery ] [ Designated as safety issue: Yes ]
  

• Conjunctival hyperemia [ Time Frame: Days 1, 3, 7, 14, and 28 after surgery ] [ Designated as safety issue: No ]
  
• Spectacle corrected visual acuity [ Time Frame: Day 28 after surgery ] [ Designated as safety issue: No ]
  

Topical steroids effectively control ocular inflammation, but are associated with the well-recognized problems of patient compliance. Injection of depot corticosteroids into sub-Tenon's capsule is an established method of treating various ocular inflammatory diseases. Its prolonged therapeutic effect has provided the ophthalmologist with an alternative tool for the treatment of different diseases that may be extended to the surgical arena to modulate postoperative inflammation. The use of topical antibiotic agents poses unique and challenging hurdles for drug delivery, especially because recent reports have suggested that the incidence of endophthalmitis may be increasing. Exploiting the permeability of the sclera, subconjunctival routes may offer a more promising alternative for enhanced drug delivery and tissue targeting compared with topical routes. In theory, the combination of an antibiotic with a steroid in a controlled-release system delivered transscleral could be feasible after cataract surgery to achieve several clinical objectives, i.e., eliminate topical medications, enhance patient compliance, improve drug bioavailability, and protect the patient from infection.